SOLO-1 Data 'Solidifies' Medicines (MDCO) as M&A Target, Partner Candidate
Tweet
Share
E-mailGet Alerts MDCO Hot Sheet
Price: $84.90 --0%
Rating Summary:
12 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
12 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Medicines Co. (Nasdaq: MDCO) is positive on the session after reporting it met the primary endpoint for the SOLO-1 Phase 3 trial.
Leerink Swann is out with comments on the news today. Analyst Joseph Schwartz said the SOLO-1 results solidify potential for M&A or a partnership.
The treatment might get a preferred hospital formulary position on the potential for it to cut the length of hospital stays and overall costs.
Schwartz sees the product bringing in $400 million to a net present value of $5 per share. Fair value estimate on Medicines is raised from $30 to $34.
Notably, Leerink is said to have had Medicines as an M&A candidate as early as November 2010.
Shares of Medicines are up about 6 percent on the session.
For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.
Shares of The Medicines Company closed at $22.29 yesterday.
Leerink Swann is out with comments on the news today. Analyst Joseph Schwartz said the SOLO-1 results solidify potential for M&A or a partnership.
The treatment might get a preferred hospital formulary position on the potential for it to cut the length of hospital stays and overall costs.
Schwartz sees the product bringing in $400 million to a net present value of $5 per share. Fair value estimate on Medicines is raised from $30 to $34.
Notably, Leerink is said to have had Medicines as an M&A candidate as early as November 2010.
Shares of Medicines are up about 6 percent on the session.
For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.
Shares of The Medicines Company closed at $22.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
Create E-mail Alert Related Categories
Analyst Comments, FDA, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
